Empowered Patient Podcast

Dr. Joel Salinas, Co-Founder and Chief Medical Officer, and Dr. Julius Bruch, Co-Founder and CEO of Isaac Health, leverage virtual care and home visits to provide proactive, technology-enabled services for early diagnosis and treatment of dementia. Their mission is to reduce barriers to cognitive assessment and improve access to personalized care plans and treatments that can delay brain disease progression. The key is respecting the patient's decisions and building trust with the care team. Joel explains, "The first thing is really just meeting people where they're at. It's so hard to get access to high-quality care due to wait times and geographic reasons. What we're building at Isaac is meant to require zero distance and move a hundred times faster than the current care journey. The other piece is we develop these partnerships where we're much more proactive about identifying changes that someone might be having with memory or thinking. We are looking at risk factors that they may have within their health record and then actually doing some outreach to those who may have some undiagnosed cognitive impairment. Part of the goal here is by meeting people when their symptoms are at their earliest, we have an opportunity of really a golden window of time to be able to bring in interventions that can impact the long-term trajectory of their brain health." Julius elaborates, "We have built a very extensive technology platform that underpins the entire care journey, from identifying and screening patients to diagnosing, treating, and care management, and seeing as you specifically asked about the diagnosis part. So once we've identified that the member is at high risk, we reach out to them and enroll them in one of our programs. The first visit is generally a medical assessment, and we use a neuropsychologist who does that initial assessment. Still, our platform guides that whole interaction to make sure that we collect all the right information in the most efficient way possible. So it's still very much over Zoom because it is the most effective way to get to the information in this population. Our platform supports the whole care flow and makes sure that it's run as efficiently as possible." #IsaacHealth #BrainHealth #DementiaCare #Caregiversupport #GUIDEModel #DigitalHealth #HealthEquity #EarlyDetection #DigitalHealthcare #Telehealth #InnovativeHealthcare #PatientEmpowerment myisaachealth.com Download the transcript here

Dr. Traci Sweet, Co-Founder and COO of Holon Health has developed an approach to treating substance use disorder that emphasizes integrating physical and behavioral health with an awareness of the impact of social determinants of health. Focusing on serving a marginalized criminal justice population that has struggled to navigate the healthcare system, Holon Health is making treatments accessible with 24/7 digital support and human-to-human interactions. Features of the Vibe app include daily affirmations, lessons, and contingency management. The key is looking forward, not revisiting the past. Traci explains, "We developed Holon Health because so many people struggle with navigating the system, particularly in terms of integrated complete treatment, for so many years now. And I've been a doctor in the field for 31 years. For so many years, we've had such a spidered system where we look at the physical health of a patient, and we look at their behavioral health and SUD needs, and we never come together to look at that in a whole body space. So Holon focuses on fully integrating care between physical health needs, substance use disorder, behavioral health, and the additional social determinants of health. So housing, employment, education. We throw everything we can at the clients. On top of that, the addition of our digital app called Holon Vibe really makes treatment accessible 365 days a year, 24/7." "We serve predominantly folks at the intersection of criminal justice and healthcare. My co-founder is formerly very enmeshed in working with the criminal justice population from his former company. I also have some Department of Corrections in my background as well. This patient has been marginalized in many ways and has found just getting through the system without judgment, without stigma, without having to focus on their shame. Their trauma has found it very difficult to navigate. So we're focused on changing that experience, moving this patient in the direction of preventative care, rewarding pro-social behaviors, and offering support that is kind of like Planet Fitness, just judgment-free. And it's been an amazing experience so far." #HolonHealth #CriminalJusticePopulation #HolisticHealthcare #SDOH #SubstanceUseDisorder holonhealth.com Download the transcript here

John Orosco, CEO and Co-Founder of Red Rover Health is focused on interoperability in the healthcare industry and the potential impact of AI and automation in streamlining healthcare processes. The emergence of revised industry-wide standards has helped improve integration, but true ease of data sharing remains elusive. An app store approach and real-time data access are the next steps in the evolution of integration methodologies, allowing providers to access the best solutions and integrate them with the core EMR systems. John elaborates, "The app store concept, which goes back to what I was saying when I started in this industry in 1998, was the approach. It was to pick the best solution regardless of the vendor that solves this departmental workflow need and let's implement the best solution. Well, integration with the core electronic medical record system was so tough and so painful and so ugly that pretty much the entire industry shifted to one vendor of record. They were like, we're just going to select one vendor. We're going to forego and give up feature functionality. We know that other solutions are better, but everything will be integrated. So, the entire industry shifts to one vendor. With the advent of APIs and interoperability becoming less painful, that was the right model." "So an app store helps facilitate this notion that any provider, regardless of where you're in the country, should have access to the best solutions that any of these vendors offer. They should be able to integrate it with the medical record. It shouldn't be up to the EMR vendors, let's say, to dictate which solutions do and don't integrate or that their solutions are the only ones that are available. A true app store concept would open the door for all these great solutions that providers would have access to, and they get to decide which ones they want to implement and use." #RedRoverHealth #HealthcareInnovation #HealthTech #Interoperability #DigitalHealth #HealthIT #AIinHealthcare #SeamlessIntegration redrover.health Download the transcript here

Mike Esworthy, Chief Strategy Officer at EnableComp, understands the challenges that health systems face when dealing with complex health claims such as workers' compensation, Veterans Administration, motor vehicle accidents, Medicaid, and out-of-state claims. These exception-based claims require deep subject matter expertise to identify the right payer and process the claims correctly. Using AI-driven technology, EnableComp helps hospitals manage complex claims, minimize the number of denials, optimize revenue, and allow them to focus on their core commercial claims. Mike explains, "I think the easiest example to provide in that context, if you look at a worker's comp claim, more often than not, when a patient comes into the hospital, they don’t know who their company's workers' comp provider is, and so often they hand over the commercial insurance card. If that doesn't get caught early, the commercial insurance gets billed, it results in a denial, and the claim sits out there in the ether for 30, 45 days before it comes back to the provider to go figure out who is the right payer class for this. So that's the big picture of the challenges. And then each of those claim types has unique nuances that make this challenging." "I think there are a lot of good things happening in the VA that are, in theory, improving access for veterans, and that's a great thing. From a claim standpoint, though, I think all of the core challenges still remain. And so I know that many of the EMRs have been putting a focus on interoperability, and all of that is great from a treatment care coordination, getting veterans seen in hospitals, and getting them through the door." "But once they've been treated, all of the same challenges that were prevalent before, all of these announcements are still out there. And I think the complexity still exists in terms of not being a normal payer pathway for providers and not knowing all the specific rules. One such example is that you were only allowed one appeal level within the veteran's claims, which means you have to get it right the first time. And so there's a really important component of knowing how to process the claim, getting it done correctly, and ensuring that you're maximizing the yield and the outcome of the claim itself." #EnableComp #VeteranCare #HealthcareInnovation #ComplexRCM enablecomp.com Download the transcript here

Dr. Neal Kassell, Founder and Chairman of the Focused Ultrasound Foundation, is working to raise awareness and drive the utilization of focused ultrasound to treat a wide range of medical conditions. This non-invasive technology uses medical imaging to precisely target and treat tissue deep in the body. Focused ultrasound has multiple mechanisms of action and can be used for destroying tumors, modulating neural activity, delivering drugs, and stimulating the immune system. Neal explains, "So focused ultrasound is a new, totally non-invasive therapeutic technology, and it's the intersection of medical imaging, which is either ultrasound or MR imaging, which is used to identify the portion of the body that we want to treat to plan the treatment, and then to guide the treatment. Then, the focused ultrasound technology delivers the energy that treats the tissue. The way it works is analogous to using a magnifying glass to focus beams of light and burn a hole in a leaf." "But at that focal point where all the beams converge, we now understand 30 ways ultrasound can affect tissue. That's in contrast to, for instance, radiation therapy, which is only one mechanism of action. Or a surgical robot, which is one mechanism of action. Focused Ultrasound has at least 30 mechanisms of action, including destroying tissue at that focal point by a variety of mechanisms, stimulating or blocking neural activity in the brain called neuromodulation, and delivering drugs or other therapeutic agents precisely to a point in the body where they are needed. This increases both the effectiveness and decreases the systemic side effects, stimulates the body's immune response to tumor, and to the effectiveness of cancer immunotherapy agents." "The point in the body where the ultrasound is targeted is, as I said, previously guided and controlled by medical imaging, either ultrasound or MR imaging. Now, the fact that there are so many different mechanisms of action creates the opportunity to treat a wide variety of medical disorders. Today, around the world, there are more than 180 clinical indications or diseases in various stages of research and development in commercialization. Ten years ago or so, there were only three. That's how rapidly the field is growing." #FocusedUltrasoundFoundation #FUSFoundation #FocusedUltrasound #Glioblastoma #ClinicalTrials #NeuroOncology #Innovation #Healthcare #MedTech #Oncology #Neurology fusfoundation.org Download the transcript here

Bryan Mazlish is CEO of Surf Bio, a company focused on novel subcutaneous formulations of biologics to enable patients to self-administer these treatments at home. The limitations of subcutaneous administration have historically made time-consuming IV infusions necessary for many biologics. The growing number of biologics and biosimilars in development will further strain the capacity of infusion centers, making subcutaneous administration a way to increase access, reduce healthcare costs, and improve patient adherence. Bryan explains, "Surf Bio is focused on enhancing the ability for patients to take a lot of the innovative and novel biologics that are currently on the market and in development. The vast majority of these historically have required a trip to the infusion center at the hospital, which is quite burdensome and takes a lot of time and resources from the patients and the healthcare system. We focus on creating novel formulations of those same drugs. These biologics can be self-administered at home in seconds instead of requiring a patient to spend the better part of the day commuting to and from an infusion center and sitting in a chair." "When you formulate biologics, they typically are formulated in water and concentrated to very high levels. They become extremely viscous and, consequently, not injectable. So, the ability to inject very high-concentration biologics subcutaneously is limited by the volume that can be administered and the concentration of the biologic that can be squeezed into that volume. As a consequence of this, historically, a large quantity of drug has been diluted at great levels and then dripped into your bloodstream through the intravenous route, which can typically take an hour or, in some cases, multiple hours." #SurfBio #BiologicsDelivery #SubcutaneousInnovation #HealthcareEfficiency surf.bio Download the transcript here

Mark Newman, CEO of Nomi Health, focuses on building an operating system for self-insured healthcare to lower costs, remove friction, and simplify the transaction process for employers and providers. Nomi emphasizes holistic preventative healthcare by eliminating barriers like deductibles and copays to encourage the utilization of primary care, mental health, and other services. The company leverages technology, AI, and asynchronous care to improve access to diverse communities, including Spanish-speaking and low-income workers. Mark explains, "Our model, starting from scratch and starting from a blank sheet of paper, is focused on getting providers out of the collection business so they can focus on the care business. Simplifying the entire transaction of buying and paying for healthcare has been a revolutionary way for our customers to cut their healthcare costs by 20% to 30%. And someday, I think we can hit 50%." "Last time I checked the cost curve in American healthcare has not slowed down and has done nothing but accelerate. So, in my book, I think value-based care has pretty much failed and has been more of a pipe dream versus reality. Our world is how do we take the same doctors, same care and cut 25% of the cost out of it by removing all the friction and pain points and ambiguity and noise as it relates to what an employer pays for healthcare and what a provider collects for delivering that healthcare. We're betting on our model and hope for the best on things like value-based care or other models, but we haven't seen the results delivered yet." #NomiHealth #HealthcareIndustry #HealthInsurance #Healthcare #HealthcareCEO nomihealth.com Download the transcript here

Maureen McBeth, Senior Medical Affairs Liaison for ImpediMed, a company that develops bio-impedance spectroscopy technology for the early detection and monitoring of lymphedema. This swelling, a common side effect of breast cancer surgery, is often overlooked until it impacts the quality of life of the patient. Using this advanced diagnostic technology, objective data on the risk and progression enables personalized intervention at the mild stage to prevent progression to severe, irreversible stages. Maureen explains, "Breast cancer-related lymphedema is an underappreciated side effect. Most people think that it's not an issue anymore because we do sentinel node biopsy. Still, we know that any time lymph nodes are removed, damaged, or radiated, they can cause problems with the plumbing system in that area of the body. And inflammation starts, and that's the first thing. People don't feel that, but over time, it starts to impact the lymphatic vessels, and those lymphatic vessels don't pump as well, and a fluid buildup starts to occur. Finally, a patient may start to have symptoms like an aching or a fullness, or they notice things don't fit right, and by the time they notice it, they're likely well into stage one lymphedema, which has noticeable symptoms." "And 20 years ago, when we didn't have these methods to detect it early, we often didn't see patients even with that at stage one. We wouldn't see them until the arm got really big and noticeable. If you can imagine, the guidelines said that the arm had to be 10% larger than the other side before we would diagnose it with lymphedema. Imagine your arm being 10% bigger on one side." "One of the important things about our technology is that it's about a 30-second test. In terms of non-invasive, the patient doesn't feel it. It gives us this L-Dex score, and we can get other things like body composition. And so, at the start of someone's treatment, it can be used not only for surveillance of lymphedema but also for other side effects of cancer treatment." #ImpediMed #EarlyDetectionMatters #LymphedemaAwarenessMonth #Survivorship #SurvivorshipCare #PatientEmpowerment impedimed.com Download the transcript here

Dr. Sam Clark, Founder and CEO of Terran Biosciences, is developing a long-acting once-daily formulation of a new class of antipsychotic drugs to treat schizophrenia. The use of a prodrug approach to modify the new drug Cobenfy allows for improved bioavailability and has been shown to have fewer side effects than traditional antipsychotics. This novel class of antipsychotic drugs targets the muscarinic receptor system, which is a different mechanism of action compared to existing treatments. Sam explains, "Schizophrenia is a very severe disease. It has both hallucinations and delusions. It also has a set of symptoms called negative symptoms, which encompass social withdrawal and symptoms that can resemble depressive symptoms, cognitive dysfunction, and memory issues. So, with this patient population, there are a number of drugs that are approved to treat schizophrenia called antipsychotics. But until now, there hasn't been a new drug approved with a new mechanism. So, all drugs have the same mechanism to treat the disease since the 1950s." "But we just got, right now in the space, a new drug approved from Bristol Myers. It just got approved, and Cobenfy is the first new mechanism to treat schizophrenia since the 1950s. But there are some downsides to that drug in that it's dosed twice daily as an oral drug, and there's currently no long-acting injectable. And so, twice daily can be difficult for patients with schizophrenia to take. The space is moving towards long-acting injectables, which can last just one injection for several months." "Now, that strategy has been used with other anti-psychotics on the market, such as Invega, to improve their bioavailability and make long-acting forms. So we took that same approach and created the long-acting prodrugs of Cobenfy, which are TerXT, those long-acting prodrugs. We believe that that will enable a once-daily form and a long-acting injectable that can go multiple months from a single injection and thus improve options for patients with schizophrenia." #TerranBio #Prodrug #Antipsychotic #Schizophrenia #MentalHealth terranbiosciences.com Download the transcript here

Joe Tucker, CEO of Enveric Biosciences, is developing non-hallucinogenic psychedelic drugs that aim to induce neuroplasticity and beneficial changes in the brains of patients with mental health disorders. The FDA rejected the approval of MDMA for PTSD treatment due to concerns about the inability to run blind trials to separate the placebo effect from the effects of the drug. Enveric addresses the promise of neuroplastic drugs that stimulate the neural connectivity between the prefrontal cortex and amygdala without hallucinations. Joe explains, "And the problem, endemic to hallucinogenic psychedelics, is that there's no question in the patient's mind, in the doctor's mind, in everybody's mind whether or not they got an hallucinogenic agent. And so when everybody knows whether they got it or not, that's what you call functional unblinding. And so the FDA was very concerned about this. They said you must be able to separate the placebo from the actual drug. Until we see data that gives us confidence that you separated it, we can't approve it, even though it looks like a very positive impact for the patients." "We were looking precisely to see if we could remove the hallucination without removing the benefit. So that's the field we're in. What's it being called right now? It's a very, very new field being called the non-hallucinogenic neuroplastogen- neuroplastogen indicating that it induces neuroplasticity, in other words, rewiring of the brain, but does so without inducing hallucination. We saw two challenges coming: How do you separate placebo from non-placebo effect and the treatment?" "Then the idea would be, hopefully, this psychedelic treatment was so impactful, you didn't need to take any other treatment again for a long period of time. And that seems pretty aspirational, honestly, and likely to get in the way of real patient acceptance that you want something which is not so sort of rock your world. Most people don't want that. They like to be able to have a drug that is like, take an aspirin. You take it every day. You don't have a big impact. You can go about your life. You don't really notice it other than you feel better. And that's the idea behind the non-hallucinogenic neuroplastogen. It fits much more in line with what patients are looking for and expecting and doctors, the whole healthcare system. It just makes a lot more sense." #MentalHealth #MentalHealthDisorders #MentalHealthEpidemic #Depression #Anxiety #PTSD #Neuroplastogens #Psychedelics enveric.com Download the transcript here

Ray Jordan is the principal at Putnam Insights, a strategic communications and policy consulting firm, and a partner at Echo Research. The core elements of reputation building are consistent across large and small companies. Many companies mistakenly think that a good reputation comes naturally, but building and maintaining a strong reputation requires a clear mission statement and an authentic voice to reinforce the company's message. Ray elaborates, "In particular, when I've worked on reputation matters, including a lot of reputation on companies, smaller companies are more instinctual rather than based on data. The core elements of reputation are still there. What you need to do is build it, what you can do to lose it, and how it adds value to what you're doing. All of those elements are consistent in some respects. Very different situations, but they have much of the same core elements. That's true from the clinical side, the regulatory side, and the patient care side. From the opinion leader side across the spectrum, including reputation communication." "So, to my mind, building it involves first knowing who and what you are and having a clear definition of yourself. The second is acting consistent with that characterization of who and what you are. The third is being seen acting that way, so being visible in those actions. Those are simple steps. They're not easy steps to accomplish, but they're simple. Who you are, how you behave, and whether you behave accordingly and are seen in that behavior." #CorporateCommunications #LeadershipInHealthcare #CrisisManagement #ESGStrategy #ReputationManagement #HealthcareLeadership putnaminsights.com echoresearch.com Download the transcript here

Dr. Shankar Musunuri, Chairman of the Board, CEO, and Co-Founder of Ocugen, is developing gene therapies for rare blindness diseases like retinitis pigmentosa and Stargardt disease, which have significant unmet medical needs. The modifier gene therapy approach aims to reset homeostasis and create a healthy environment for photoreceptors to stabilize vision loss. Ocugen is also working on a gene therapy for dry age-related macular degeneration, which has the potential to address the late-stage geographic atrophy form of the disease. Shankar explains, "Vision is the most important part for all of us. Many years ago, when we founded Ocugen, it was based on targeting the ophthalmology disease area. We looked into many blindness diseases related to the back of the eye/retina. We have diseases such as AMD- and many people get into that – age-related macular degeneration. Then, there are diseases that are inherited in nature, like retinitis pigmentosa and Stargardt disease. A lot of these diseases impact many families globally. Therefore, our passion for patients has driven that. If there is a significant unmet medical need, we want to take that as a challenge and provide solutions for patients and provide that hope." "There are two rare blindness diseases. One is retinitis pigmentosa. There are about two million people globally who struggle with it. About 300,000 patients are in the US and EU. Effects in about 100 genes can cause retinitis pigmentosa. With our modifier game-changing gene therapy technology, potentially, our one product, which is currently going through a Phase 3 clinical trial, can target this entire population, rather than building or developing 100 products with the traditional gene therapy gene. The second inherited retinal disease we are working on, Stargardt, affects about 100,000 patients in the US and EU. Similar to RP, there are no therapies today to treat these patients’ significant unmet medical needs." #Ocugen #CourageousInnovation #GeneTherapy #ModifierGeneTherapy #BlindnessDiseases #RetinitisPigmentosa #GeographicAtrophy #Stargardt ocugen.com Download the transcript here

Allen Cooper, President, CEO, and Co-Founder of ReadyList, highlights the challenges environmental services (EVS) leaders face in hospitals: controlling healthcare-associated infections, managing facility maintenance, and meeting patient expectations. Ensuring efficient room turnover for patient rooms and operating rooms is critical to maintaining workflow and avoiding delays. Real-time tracking, task management, and data-driven insights help EVS managers and staff eliminate outdated, inefficient methods and improve patient outcomes and safety in hospital operations. Allen explains, "When you look at it from a patient's perspective, I think meeting and exceeding patients’ expectations of getting great quality care is probably at the forefront of everyone's mind. There's a lot of competition out there between hospitals and health systems. I think, looking from a patient's point of view, making sure that the patients are delighted is number one. A close number 2, if not number 1, is making sure that the hospitals themselves are controlling and reducing their healthcare-associated infections. I think that's been such a hot topic in the last 10-plus years, making sure that the patients are safe and taken care of, and when they leave, they're in a better spot than before they came." "We have four core modules of ReadyList. One is called ReadyList Room Care, which empowers the EVS cleaners to understand what's expected of them to turn over a room in a given day or hour. And it details out what's expected in a given room. Each unit in the hospital typically has different requirements and ensures that the equipment is what is actually supposed to be in place and that cleaning is done appropriately and done repeatedly the same way every single time. So the tool provides almost like a script for the cleaners so they understand exactly what their expectations are. On the flip side, for the supervisors, it also allows them to understand exactly what is going on, which rooms are cleaned or being cleaned, and who's doing what." #ReadyList #HospitalOperations #EVSManagement #EVSLeader #EnvironmentalService #EVS #HospitalFloorcare #FacilityOperation #Healthcare #HospitalSafety #HospitalInfectionPrevention ReadyList.com Download the transcript here

Sheila Phicil, Founder and CEO of Phicil-itate Change, works with innovators in healthcare to apply new technologies to solutions that incorporate the patients' voice. One goal is to reduce resistance to change, which often stems from the desire to avoid adding more complexity, by listening to patients, physicians, and community organizations. Data analytics and awareness of social determinants of health can provide insights to develop effective and sustainable solutions. Still, the data must be collected and analyzed in a way that preserves the context and individual experience. Shelia explains, "Well, the simplest way I can put it is helping the helpers and in this case, it's helping people who want to bring forward good innovation in healthcare. To do it well by focusing the work around the patient's lived experience through understanding their stories and their health data. So what I'm aiming to do is to, one, put out great frameworks and strategies around how to do this well and efficiently and effectively. We are building a platform utilizing blockchain and AI to automate some of this work in collecting patient stories and data and generating insights into how to design health tech solutions that meet their needs." "So all forms of social innovation, where we're trying to solve human problems, should always start with the people who have lived the experience of the problem and understand through their lens what their perspective is. What I often tell people, especially in the healthcare space, is that someone who has a lived experience of having diabetes or lost a loved one to cancer or is dealing with a rare disease, they become the expert. They become the expert in what that looks like for them, how that affects their life, and what they can tolerate in terms of coping or treatment and other things." #SocialDeterminantsofHealth #SDOH #MedTech #DataAnalytics Phicil-itateChange.com Download the transcript here

Lisa Ricciardi, CEO, and Dr. Tony Caggiano, Chief Medical Officer at Cognition Therapeutics, are developing effective treatments for neurological disorders, particularly Alzheimer's disease and dementia with Lewy bodies (DLB). While DLB is related to Parkinson's, sharing symptoms include hallucinations, sleep disorders, and cognitive dysfunction, there are no good diagnostics to identify DLB and effective treatments. Cognition Therapeutics' lead drug candidate, an oral treatment, has shown promise in protecting neurons from the toxic effects of the pathological proteins involved in Alzheimer's and DLB. Lisa explains, "This company started in 2007, so we've had a long number of years to burnish our mission. One of the things we say is we're the beginning of the end of neurologic disorders and the start of hope for an improved future for patients. So Alzheimer's disease, in particular, has been long studied with little success, and in the last few years, we've seen some successes with monoclonal antibodies. There are a number of other approaches in clinical trials, but we have recently generated very positive data in two different trials with an oral once-a-day drug." Tony elaborates, "Lewy body dementia or dementia with Lewy bodies is a disease very much related to Parkinson's disease that's believed to be, in part, caused by pathological levels of a certain protein called alpha synuclein and particularly small oligomers of misfolded alpha synuclein." "And in Alzheimer's disease, this is largely a cognitive memory disorder as it presents. So, those two diseases are very different. Now, the idea of treating them with a single drug is somewhat unique to what we have here at Cognition Therapeutics. So our company started around the idea of developing therapies for Alzheimer's disease, and our lead molecule CT1812 or zervimesine was developed out of a screening assay where we were looking for molecules that could protect neurons or brain cells from the toxicities of this pathological amyloid protein. So, we identified CT1812 and have been developing it." #CognitionTherapeutics #BrainHealth #DementiaCare #LewyStrong #Livingwithlewy #Alzheimers #EndAlz #Alzheimersdisease #DLBAwareness #NeurodegenerativeDisease #Dementia #DementiaWithLewyBodies cogrx.com Download the transcript here

Arielle Smith, the President of Life Science at Event Cadence, discusses the changes in the event technology landscape and the expectations of pharmaceutical companies and attendees for a hybrid approach, including participation in person and virtually. There is an increased demand for insight capturing and analytics to measure the return on investment in conferences and the time attendees spend there. The platform includes scheduling, appointment management, and lead generation with tools to encourage networking and interaction to enhance the event experience. Arielle explains, "Medical conferences are held all over the world, as you know, and there's not always going to be a time where you can physically put boots on the ground and travel for them. So we're seeing a lot more of a hot tier point, a hybrid model approach to it where, let's say, the majority of the team will be in a meeting room face to face with some of their HCPs, but then even that HCP might decide to dial in their counterpart. Or if a pharmaceutical client is not able to participate in person for many different reasons, we're looping them in from a virtual perspective as well. And our platform can help coordinate all of that." "So there's a lot of talk in the industry about insight capturing and gathering and exactly how that can be done but how best to make it actionable. Many great platforms are spinning up recently that are meant for capturing recordings or recording a conversation like the one you and I are having now, but then using AI to transcribe it all. A lot of our accounts are playing with technology like that, and then our platform is being used to set those conversations up." #EventCadence #MedicalConferences #ConferenceManagement #HybridConferences eventcadence.com Download the transcript here

Dr. Thomas Chen, Founder, CEO, and CSO of NeOnc Technologies, is working on the challenge of delivering drugs across the blood-brain barrier by using an intranasal delivery approach to target brain cancers. This delivery platform leverages the cranial nerve to transport the drugs directly to the brain, bypassing the blood-brain barrier. Genomic analysis of the long-surviving patients in the phase one trial revealed a common genetic mutation, informing the trial design for the next phase. Thomas explains, "So our platform is what we call intranasal delivery. And with the intranasal delivery, we're not trying to cross the blood-brain barrier. We're trying to cross over it. And how we're doing that is doing the delivery of the drug via what we call the C nerves. Now the cranial nerves are, we have 12 cranial nerves in our brain. These cranial nerves have various functions, but the cranial nerves involved with the nasal brain delivery are the first and the fifth cranial nerves. The first cranial nerve is what we call the olfactory nerve. That's the nerve that's responsible for smell. The fifth cranial nerve is called the trigeminal nerve, which involves facial sensation and allows us to chew." "So what happens is that when we want to deliver the drug to the brain cancer, we have the patient inhale it. When the patient inhales, it goes through the nose, and through the olfactory nerve, it goes to the brain. Usually, that molecule then absorbs in the spinal brain and then circulates to the target, in this case, brain cancer. Now you know how powerful that cranial nerve is from the standpoint of what it does when you smell something, that scent, that odor gets transported from the olfactory nerve to our brain. And that's basically what we're doing. We're taking something external to the brain, allowing the cranial nerve to absorb and transport it to the brain." #NeOnc #BloodBrainBarrier #BBB #BrainCancer #DrugDelivery neonc.com Download the transcript here

Ali Morin, Chief Nursing Informatics Officer at symplr, emphasizes the need to focus on the challenges nurses face and AI's potential to reduce administrative burdens and nurse burnout. Significant staffing shortages, scheduling challenges, and increased patient acuity demand better data analytics and technology implementation to allow nurses to spend more time with patients and improve patient care. For successful integration of technology solutions into the nurses' workflow, pilot tests, training of new and experienced nurses, and listening to their concerns and ideas are essential. Ali explains, "We focus on the nursing informatics side -- that middle communicator between technology and the nurses at the bedside. So, I consider myself a translator. I listen to the clinicians and the nurses who are using our software, and we have a number of solutions that are applicable for direct care nurses as well as nurse managers and nurse leaders. I take in the pain points that they're experiencing today and bring them to our developers and our product teams. This allows them to understand the pain points that nurses are experiencing and how we can help solve some of those problems." "However, we're taking it to the next level and putting in some additional machine learning around which nurses are still available to pick up shifts and which nurses are still available who haven't maybe met their core component. Today, how that's done: there are spreadsheets, call lists, and post-it notes all over the place. Who have I called? Who have I checked with? Who hasn't seen this manual kind of back-and-forth? And so our work is really to make that balancing phase of the nursing scheduling simpler, pun intended, 100%, but also simpler so that we can make it so those nurses and nurse managers, the nurses can say, I want to work these kinds of shifts. The nurse managers can say, great, plug them in, and off they go. And then it's less time in that kind of back and forth between them." #symplr #Nurses #HealthTech #HealthcareAI #CompassSurvey symplr.com Download the transcript here

Maggie Cline, Executive Director at EyeCare4Kids Utah, highlights the importance of providing eye exams and eyeglasses to underserved children, their parents, and those in shelters, refugee camps, and Native American reservations. Early testing and glasses with the correct prescription can significantly impact academic performance, confidence, and social skills. Making wearing glasses cool and offering a wide selection of frames is key to encouraging everyone to wear them proudly. The EyeCare4Kids partners with various organizations to operate brick-and-mortar and mobile clinics in Utah, Nevada, Arizona, Idaho, and Africa with expansion plans. Maggie explains, "I think glasses are cool these days, but the kids have to wear their glasses. So something that we do, and I love that we do this, we don't just give them a selection of five or six glasses. They get hundreds to choose from because we know that if they feel good about what they're wearing, they will wear them. And so I just got a message from a nurse the other day telling me she has been so happy seeing these students proudly wearing their glasses. They absolutely love them, and they show them off. They tell their friends about them." "There are a lot of barriers. There are parents who are working, and in many of the homes just here in the US, both parents are working, so there's just no time. They don't want to take them out of school. I think there's just a lot of different reasons. I think there needs to be more education for parents to be able to notice the signs. Maybe kids have behavioral problems in the classroom that are often misdiagnosed. A kid sitting at the back of the classroom who isn't able to see the PowerPoint or the board is probably just unable to focus because they can't see clearly." "For example, our team was dispensed at an elementary school. There was a first grader who put on his pair of glasses, his first pair of glasses, and he had a significant prescription, and there was a brick wall right next to him. He was just amazed at the brick wall and that it had texture, and he just kept feeling it and talking about it. Then he looked at the school staff and was like, I can see your face. And they were just so amazed at the different details he could see." #ChildrensVisionCare #PediatricVisionCare #Glasses4Kids #EyeGlasses EyeCare4Kids.org Download the transcript here

Olivier Visa, President and CEO of Evergen specializes in developing and manufacturing biomaterials for use in regenerative medicine. These customized biomaterial solutions use xenografts, allografts, and emerging technologies inside and outside the body with applications in wound healing, cardiac, dental, breast, neuro, and spine repair. This approach provides surgeons with a broader range of biomaterials to better tailor treatments for individual patients. Olivier explains, "There is a multitude that we can support. There is form and function, and I can give you a couple of examples of biomaterials in regenerative medicine. One is bovine pericardium, which is bovine collagen that we use for the development and manufacturing of cardiac heart valves. Another one would be acellular dermal matrix from human tissue that we use for reconstruction in plastic and, of course, with surgeries such as breast reconstruction after mastectomy." "Think about the body as a whole, and I'll give you a couple of examples where- when you're in cardiac - whether it's a patch or a valve, we're inside the body. When we're in breast reconstruction, we are totally inside the body. When we're in the neuro spine, we're totally inside the body, whether you're repairing or restoring or regenerating peripheral nerves or dura around the brain, you're inside the body. And yes, you are right, wound management is part of it, whether it's diabetic food, ulcer, ulcer or some form of a burn, then I would say you're looking at the skin as an organ and repairing, restoring, and regenerating that skin." #Evergen #TissueEngineering #RegenerativeMedicine #CDMO #Biomaterials #Biotechnology #LifeSciences #MedicalDevices #SportsMedicine #Orthopedics #Surgeons evergenbio.com Download the transcript here